GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Resectable MAGE-A3 Positive Non-Small Cell Lung Cancer
Phase 3
- Conditions
- on-Small Cell Lung Cancer
- Registration Number
- JPRN-jRCT2080220584
- Lead Sponsor
- GlaxoSmithKline K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Refer to 'GSK Clinical Study Register'
Exclusion Criteria
Refer to 'GSK Clinical Study Register'
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Refer to 'GSK Clinical Study Register'<br>Refer to 'GSK Clinical Study Register'
- Secondary Outcome Measures
Name Time Method Refer to 'GSK Clinical Study Register'<br>Refer to 'GSK Clinical Study Register'